Please login to the form below

Not currently logged in
Email:
Password:

methotrexate

This page shows the latest methotrexate news and features for those working in and with pharma, biotech and healthcare.

FDA panel undermines Lilly and Incyte’s baricitinib hopes

FDA panel undermines Lilly and Incyte’s baricitinib hopes

methotrexate, but concluded that the higher 4mg dose - while effective - may not be sufficiently safe based on the submitted data.

Latest news

  • AbbVie’s upadacitinib aces phase III trial AbbVie’s upadacitinib aces phase III trial

    The results were achieved in patients with moderate-to-severe RA who were being treated with methotrexate but whose symptoms were not being controlled.

  • Lilly claims another EU okay for Taltz Lilly claims another EU okay for Taltz

    Lilly claims another EU okay for Taltz. The IL-17 inhibitor can be used alone or in combination with methotrexate for PsA patients. ... The new approval means that Taltz can be used either alone or in combination with methotrexate for PsA patients who

  • AbbVie’s JAK inhibitor upadacitinib clears another phase III trial AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

    Its earlier trials in RA have compared the drug to placebo on top of methotrexate therapy. ... response) after switching from methotrexate therapy, compared to 41% who remained on that regimen.

  • NICE backs Pfizer’s Xeljanz for RA NICE backs Pfizer’s Xeljanz for RA

    Given in combination with methotrexate, the twice-daily administered drug is recommended for adults whose disease hasn’t responded adequately to intensive therapy with conventional or other disease-modifying anti-rheumatic ... Additionally, the drug

  • NICE backs Sanofi's Kevzara for routine NHS use NICE backs Sanofi's Kevzara for routine NHS use

    NICE backs Sanofi's Kevzara for routine NHS use. Recommends the RA treatment in combination with methotrexate. ... Given in combination with methotrexate, the drug maker’s IL-6 inhibitor will be made available for routine use under the NHS for adults

More from news
Approximately 2 fully matching, plus 100 partially matching documents found.

Latest appointments

  • Antares appoints David Bergstrom as SVP Antares appoints David Bergstrom as SVP

    The appointments come as the company looks to expand its business after the commercialisation of Otrexup (methotrexate) for arthritis and the advance in development of testosterone replacement therapy Vibex QS T.

  • Former Pfizer VP joins Antares Former Pfizer VP joins Antares

    methotrexate) for arthritis and advance the development of testosterone replacement therapy Vibex QS T. “

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics